Patent · US Active

Modified Fc gamma receptor type III (FcgammaIII, HNA-1) polypeptides and the uses thereof

US11460470B2 · kind B2 · utility

0Cited by

0References

1Claims

0Family size

Assignee

One Lambda, Inc. · US

Inventors

Jar-How Lee · Los Angeles, US
Neng Jen Remi Shih · Calabasas, US
Julie Nguyen · Santa Clarita, US
Rui Pei · Fullerton, US

Key dates

Filing date	Feb 5, 2020
Grant date	Oct 4, 2022
Priority date	—
Expiry date	Mar 4, 2041

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/245
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention is directed to engineered Fc gamma receptor type III (FcγII, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.